Figure 6.
Drug sensitivity in high-risk score patients and the immune and molecular subtypes. (A) Four CTRP-derived compounds (including SB-743921, GSK461364, gemcitabine, and paclitaxel); (B) Two PRISM-derived compounds (including dolastatin-10 and LY2606368); (C) Relationship between immune subtypes and the risk signature. ** indicate P < 0.01; *** indicate P < 0.001.